The overall expansion will add almost 50% more manufacturing space for current production.
UPM’s President, James Gregory, said, “ To meet our client’s growing needs, UPM is making a major capital commitment to enhance client services. In response to an increasing number of requests for production of compounds with more stringent environmental safety requirements, UPM is building a unique suite for handling of manufacturing processes associated with OEB 4 compounds. We are also building a dedicated suite for handling and production of low humidity compounds. Finally, as a leader in providing neat API direct-fill-in-a-capsule services using the latest Xcelodose technology, UPM will be developing a unique segregated four room suite to handle Xcelodose processing and encapsulation activities associated with the 600 and 600S equipment systems. We intend to provide these services under the most strict handling conditions up to and including OEB 4 compounds. With the outstanding service being provided by our skilled R&D, manufacturing, laboratory, and Quality Assurance teams, UPM’s business is dramatically growing. This expansion will allow us to keep pace with our clients’ needs and continue our commitment to speed and quality in the services we provide.”
About UPM Pharmaceuticals
UPM Pharmaceuticals, Inc. is a Baltimore-based, independent drug development and contract manufacturer serving the pharmaceutical and biotechnology industries. They provide high quality pharmaceutical drug development services including formulation development, cGMP manufacturing, analytical methods development and stability testing. They are characterized by the quality, speed and thoroughness with which they complete all their projects. UPM’s clients enjoy service that is customized and fast with total quality management characteristic of a customer-focused business. Their history includes successful collaborative interactions with virtual to multi-million dollar companies providing them with customized product development services and solutions. UPM focuses on drug development for dosages with oral routes of administration, in solid dosage forms such as capsules and tablets.
To learn more about UPM, please visit the Web site at http://www.upm-inc.com/
UPM Pharmaceuticals is a registered U.S. trademark.